Editorials
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7349.1287 (Published 01 June 2002) Cite this as: BMJ 2002;324:1287Related articles
- Editor's Choice Published: 01 June 2002; BMJ 324 doi:10.1136/bmj.324.7349.0/h
- Correction Published: 29 June 2002; BMJ 324 doi:10.1136/bmj.324.7353.1538
- Primary Care Published: 01 December 2005; BMJ 331 doi:10.1136/bmj.331.7528.1310
- Paper Published: 05 May 2005; BMJ 330 doi:10.1136/bmj.38414.422650.8F
- PAPERS Published: 07 April 2005; BMJ doi:10.1136/bmj.38414.422650.8F
- Letter Published: 20 July 2002; BMJ 325 doi:10.1136/bmj.325.7356.161
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1474-c
- Primary Care Published: 09 June 2005; BMJ 330 doi:10.1136/bmj.330.7504.1366
- Research Published: 27 October 2020; BMJ 371 doi:10.1136/bmj.m3764
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- Proton pump inhibitors and community acquired pneumoniaBMJ November 17, 2016, 355 i6041; DOI: https://doi.org/10.1136/bmj.i6041
- NSAIDs and the failing heartBMJ September 28, 2016, 354 i5163; DOI: https://doi.org/10.1136/bmj.i5163
- Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control studyBMJ September 28, 2016, 354 i4857; DOI: https://doi.org/10.1136/bmj.i4857
- Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trialBMJ August 18, 2016, 354 i4079; DOI: https://doi.org/10.1136/bmj.i4079
Cited by...
- Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study
- When drugs don't make it to market
- Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib
- An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
- The Drug Effectiveness Review Project: An Important Step Forward
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
- Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks
- Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
- Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study
- Taking stock of coxibs
- Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials
- Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial
- Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib
- Lessons from the withdrawal of rofecoxib
- Analgesia for patients with advanced disease: 2
- Non-surgical treatment of osteoarthritis: a half century of "advances"
- Drug company sues Spanish bulletin over fraud claim
- Why don't we initiate more large simple randomized controlled trials?
- CLASS clarification: reaffirms the medical importance of the analyses and results
- New dogmas or old?
- Failures of the therapeutic chain as a cause of drug ineffectiveness
- Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
- Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis
- The double-edged sword of COX-2 selective NSAIDs
- US Food and Drug Administration gets it right
- JADA INDUSTRY ADVISORY BOARD
- Efficacy and safety of COX 2 inhibitors
- Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs
- Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials
- Are selective COX 2 inhibitors superior to traditional NSAIDs?
- Potential alternatives to COX 2 inhibitors